| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | -0.073 | 0.02 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | -0.066 | 0.02 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | LAQ824 | GDSC1000 | pan-cancer | AAC | -0.081 | 0.02 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | -0.18 | 0.02 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.077 | 0.02 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.13 | 0.02 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | -0.077 | 0.02 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.086 | 0.03 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.11 | 0.03 |